HC Wainwright Has Negative Outlook of ATOS FY2026 Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Investment analysts at HC Wainwright decreased their FY2026 EPS estimates for Atossa Therapeutics in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.32) per share for the year, down from their prior estimate of ($0.21). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2027 earnings at ($0.27) EPS and FY2028 earnings at ($0.21) EPS.

Atossa Therapeutics (NASDAQ:ATOS) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01.

Other analysts have also recently issued reports about the stock. StockNews.com cut shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 8th. Ascendiant Capital Markets boosted their price objective on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research report on Wednesday, September 11th.

Atossa Therapeutics Stock Performance

ATOS opened at $1.37 on Friday. The business has a 50 day moving average price of $1.44 and a 200 day moving average price of $1.38. Atossa Therapeutics has a twelve month low of $0.63 and a twelve month high of $2.31.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in Atossa Therapeutics during the second quarter worth about $29,000. Intech Investment Management LLC bought a new stake in shares of Atossa Therapeutics in the 3rd quarter worth approximately $29,000. SG Americas Securities LLC increased its position in shares of Atossa Therapeutics by 254.3% during the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares during the period. Cetera Advisors LLC acquired a new position in shares of Atossa Therapeutics in the first quarter valued at $72,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Atossa Therapeutics during the third quarter worth $75,000. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.